Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,281,483
  • Shares Outstanding, K 77,777
  • Annual Sales, $ 380,830 K
  • Annual Income, $ -715,080 K
  • 60-Month Beta 1.99
  • Price/Sales 19.60
  • Price/Cash Flow N/A
  • Price/Book 8.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -2.17
  • Number of Estimates 8
  • High Estimate -1.62
  • Low Estimate -3.11
  • Prior Year -1.07
  • Growth Rate Est. (year over year) -102.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.06 +19.93%
on 03/18/20
123.96 -24.48%
on 03/05/20
-22.48 (-19.36%)
since 03/03/20
3-Month
78.06 +19.93%
on 03/18/20
134.57 -30.43%
on 01/10/20
-36.16 (-27.86%)
since 01/03/20
52-Week
72.05 +29.94%
on 09/26/19
158.80 -41.05%
on 07/15/19
-29.06 (-23.69%)
since 04/03/19

Most Recent Stories

More News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2020 that were previously approved by the Compensation Committee...

SRPT : 93.62 (-2.46%)
Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SRPT : 93.62 (-2.46%)
Look for Shares of Sarepta Therapeu to Potentially Rebound after Yesterday's 1.80% Sell Off

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $102.69 to a high of $111.85. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of...

SRPT : 93.62 (-2.46%)
Sarepta Therapeu Rises 3.25% on Heavy Volume: Watch For Potential Pullback

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $116.23 to a high of $123.06. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high...

SRPT : 93.62 (-2.46%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020 that were previously approved by the Compensation Committee...

SRPT : 93.62 (-2.46%)
Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

RHHBY : 41.1200 (-1.27%)
VRTX : 238.31 (-1.59%)
SRPT : 93.62 (-2.46%)
CLVS : 6.10 (+0.49%)
Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program

-- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

SRPT : 93.62 (-2.46%)
Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

Antisense Therapeutics Limited (ASX:ANP) is pleased to advise of the appointment of Gil Price M.D. as Consultant Medical Director.

ATHJF : 0.0210 (-12.50%)
SRPT : 93.62 (-2.46%)
IONS : 48.51 (-1.02%)
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -72.68% and 0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?...

SRPT : 93.62 (-2.46%)
Sarepta Therapeutics: 4Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $235.7 million in its fourth quarter.

SRPT : 93.62 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade SRPT with:

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

2nd Resistance Point 99.84
1st Resistance Point 96.73
Last Price 93.62
1st Support Level 91.26
2nd Support Level 88.89

See More

52-Week High 158.80
Fibonacci 61.8% 125.66
Fibonacci 50% 115.43
Fibonacci 38.2% 105.19
Last Price 93.62
52-Week Low 72.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar